WP
ALNY icon

WealthPLAN Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

WealthPLAN Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-250
Closed -$11.9K – 192
2017
Q1 		$11.9K Buy
+250
New +$11.6K 0.04% 244
2016
Q3 		$17.1K Sell
250
-250
-50% -$17.6K 0.01% 510
2016
Q2 		$13.9K Buy
+500
New +$31.5K ﹤0.01% 1594
2015
Q4 		$23.6K Buy
+750
New +$69.5K ﹤0.01% 863

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

WealthPLAN Partners's ALNY Position: Q2 2017 in Review

WealthPLAN Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2017, closing a stake of 250 shares — an estimated $11.9K sold.

WealthPLAN Partners first reported a position in ALNY in Q4 2015 and held it in 4 quarters. The position peaked at $23.6K in Q4 2015. 227 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

  • WealthPLAN Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • WealthPLAN Partners sold 250 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $11.9K.
  • WealthPLAN Partners first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 4 quarters.
  • WealthPLAN Partners's Alnylam Pharmaceuticals position peaked at $23.6K in Q4 2015.
  • 227 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on WealthPLAN Partners's 13F filing for Q2 2017, filed 11 Aug 2017.